🇺🇸 FDA
Pipeline program

Orelabrutinib

ZB020-03-002

Phase 3 small_molecule active

Quick answer

Orelabrutinib for Secondary Progressive Multiple Sclerosis is a Phase 3 program (small_molecule) at Zenas BioPharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Zenas BioPharma
Indication
Secondary Progressive Multiple Sclerosis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials